GlobeNewswire Inc.··Biocryst Pharmaceuticals, Inc.BioCryst Lands $70M Deal, Reports ORLADEYO Growth Ahead of Navenibart Catalyst
BioCryst posts 11% ORLADEYO revenue growth to $148.3M in Q1 2026, inks $70M European licensing deal for navenibart with up to $275M in milestones.
BCRXrevenue growthclinical trial